Quality assessmentNo of patientsEffectQuality
No of studiesDesignRisk of biasInconsistencyIndirectnessImprecisionOther considerationsCoal tar
Mean time to maximum response (% change in PASI) (follow-up 6 weeks)
1
Thawornchaisit 2007		observational studiesano serious risk of biasbno serious inconsistencyno serious indirectnessno serious imprecisionnone10% liquor carbonis detergens

28		Mean PASI and % change in PASI score from baseline⊕⊕○○
LOW
2 weeks14.83±3.0
−13.56±8.5%
4 weeks12.31±3.3
−28.18±16.5%
6 weeks10.60±4.1
−38.39±21.1%
Mean time to maximum response (% change in PASI) (follow-up 6 weeks)
1
Tham 1994		observational studiesano serious risk of biasbno serious inconsistencyno serious indirectnessno serious imprecisionnoneLiquor picis carbonis

27		Mean PASI and % change in PASI score from baseline⊕⊕○○
LOW
Baseline12.95±3.4
2 weeks5.9±4.5
−9.4±15.9%
4 weeks5.1±4.2
−22.3±24.2%
6 weeks4.5±3.6
−30.9±24.6%
Mean time to maximum response (% change in mPASI [0–64.8]) (follow-up 12 weeks)
1
Alora-Palli 2010		observational studiesano serious risk of biasbno serious inconsistencyno serious indirectnessno serious imprecisionnoneLiquor carbonis detergens

27		% change in PASI (0–64.8) from baseline⊕⊕○○
LOW
Baseline7.3
4 weeks4.69 (−35.4%)
8 weeks3.70 (−48.9%)
12 weeks3.24 (−58.2%)
Mean time to maximum response (TSS; follow-up 8 weeks)
1
Pinheiro 1997		observational studiesano serious risk of biasbno serious inconsistencyvery seriouscvery seriousdnoneAlphosyl HC

65		The maximum response based on mean TSS was seen at 4 weeks, with no further improvement up to 8 weeks⊕⊕○○
LOW
a

Although the data are taken from randomised trials the benefit of control data is not being utilised as considerations are being made based on single interventions without reference to the comparator arm

b

Unclear allocation concealment may have biased patient selection for this intervention

c

Incorrect outcome measure

d

Interpreted from graphical representation

From: 8, Topical therapy

Cover of Psoriasis
Psoriasis: Assessment and Management of Psoriasis.
NICE Clinical Guidelines, No. 153.
National Clinical Guideline Centre (UK).
Copyright © National Clinical Guideline Centre - October 2012.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Clinical Guideline Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.